miR Scientific, LLC
Par un écrivain mystérieux
Description
miR Scientific, LLC | 1 395 abonnés sur LinkedIn. miR Scientific is a healthcare company that is committed to transforming cancer management globally. | miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management Platform®, a proprietary, non-invasive platform for the effective management of targeted diseases, initially focused on urological cancers. The platform is powered by the miR Sentinel® Prostate Cancer Test, a liquid biopsy urine test that can accurately detect, classify, and monitor prostate cancer based on the interrogation of small-non-coding RNAs extracted from urinary exosomes. miR Scientific is developing interoperable products and services necessary to revolutionize the standards of care supporting urologic oncology, including for prostate, bladder, and other urothelial cancers.
miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management Platform®, a proprietary, non-invasive platform for the effective management of targeted diseases, initially focused on urological cancers. The platform is powered by the miR Sentinel® Prostate Cancer Test, a liquid biopsy urine test that can accurately detect, classify, and monitor prostate cancer based on the interrogation of small-non-coding RNAs extracted from urinary exosomes. miR Scientific is developing interoperable products and services necessary to revolutionize the standards of care supporting urologic oncology, including for prostate, bladder, and other urothelial cancers. Such new standards are urgently needed given the prevalence of these cancers and their debilitating burden globally. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in New York City with operating subsidiaries in Israel, Canada, and Puerto Rico.
miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management Platform®, a proprietary, non-invasive platform for the effective management of targeted diseases, initially focused on urological cancers. The platform is powered by the miR Sentinel® Prostate Cancer Test, a liquid biopsy urine test that can accurately detect, classify, and monitor prostate cancer based on the interrogation of small-non-coding RNAs extracted from urinary exosomes. miR Scientific is developing interoperable products and services necessary to revolutionize the standards of care supporting urologic oncology, including for prostate, bladder, and other urothelial cancers. Such new standards are urgently needed given the prevalence of these cancers and their debilitating burden globally. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in New York City with operating subsidiaries in Israel, Canada, and Puerto Rico.
Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy
Puerto Rico to Test miR's 'Liquid Biopsy' in Detecting Prostate Cancers
.png)
miR Scientific
Samantha Mall - Senior Research Associate - Assay Development - miR Scientific, LLC
miR Scientific, LLC on LinkedIn: #prostatecancer #cancer #accurate #noninvasive #urinetest…
miR Sentinel™ The Future Of Prostate Cancer Tests
miR Scientific
miR Sentinel™ The Future Of Prostate Cancer Tests
Sponsors Fifth Global Summit on Precision Diagnosis and Treatment of Prostate Cancer – September 23-25, 2021 – AdMeTech
miR Scientific, LLC on LinkedIn: #prostatecancer #urology #menshealth
Mir Imran - Wikipedia
miR-486 is essential for muscle function and suppresses a dystrophic transcriptome
miR Scientific
miR Sentinel™ Press Release
miR Scientific announces FDA Breakthrough Device Designation for its Prostate Cancer Liquid Biopsy Test
depuis
par adulte (le prix varie selon la taille du groupe)
